J Breast Cancer. 2012 Sep;15(3):273-82. doi: 10.4048/jbc.2012.15.3.273. Epub 2012 Sep 28.
Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells TargetCancer Cells In Situ.
Source
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA. ; Department of Medicine, Harvard Medical School, Boston, USA. ; Department of Biomedical Engineering, Tufts University, Medford, USA.
Abstract
PURPOSE:
Tumor-specific delivery of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), an apoptosis-inducing peptide, at effective doses remains challenging. Herein we demonstrate the utility of a scaffold-based delivery system for sustained therapeutic cell release that capitalizes on the tumor-homing properties of mesenchymal stem cells (MSCs) and their ability to express genetically-introduced therapeutic genes.
METHODS:
Implants were formed from porous, biocompatible silk scaffolds seeded with full length TRAIL-expressing MSCs (FLT-MSCs). under a doxycycline inducible promoter. In vitro studies with FLT-MSCs demonstrated TRAIL expression and antitumor effects on breast cancer cells. Next, FLT-MSCs were administered to mice using three administration routes (mammary fat pad co-injections, tail vein injections, and subcutaneous implantation on scaffolds).
RESULTS:
In vitro cell-specific bioluminescent imaging measured tumor cell specific growth in the presence of stromal cells and demonstrated FLT-MSC inhibition of breast cancer growth. FLT-MSC implants successfully decreased bone and lung metastasis, whereas liver metastasis decreased only with tail vein and co-injection administration routes. Average tumor burden was decreased when doxycycline was used to induce TRAIL expression for co-injection and scaffold groups, as compared to controls with no induced TRAIL expression.
CONCLUSION:
This implant-based therapeutic delivery system is an effective and completely novel method of anticancer therapy and holds great potential for clinical applications.
No comments:
Post a Comment